Net income surged 54% to $40.2 million for the quarter.
Operating margins expanded from 5.4% to 8.3%.
Refinanced previous debt into a $325M senior secured term loan.
Received NYSE notice of non-compliance with minimum share price requirements.
The latest filing reveals a company in a high-stakes transition, balancing impressive top-line diversification against a volatile balance sheet. While the shift toward healthcare services and pharmacy is driving revenue growth and improving short-term net income, the underlying capital structure remains a primary concern for investors. The reduction in interest expense provides temporary breathing room, but the looming redemption requirements of the senior preferred stock and the variable nature of the new term loan create a high-risk environment. Ultimately, the investment case depends on whether the operational momentum in healthcare services can outpace the financial pressure of its debt and the legal headwinds from ongoing DOJ and securities litigation. The immediate catalyst will be the company's ability to regain NYSE compliance and stabilize its share price, as a delisting would likely trigger a liquidity crisis that could overshadow its operational wins.